PIN37 COST EFFECTIVENESS ANALYSES (CEA) OF LOPINAVIR/RITONAVIR (LPV/R) AND ATAZANAVIR PLUS RITONAVIR (ATV VE HIV-I INFECTED PATIENTS BASED ON CASTLE 48-WEEK STUDY- APPLICATION TO GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM
May 1, 2010, 00:00
10.1016/S1098-3015(10)72944-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)72944-2/fulltext
Title :
PIN37 COST EFFECTIVENESS ANALYSES (CEA) OF LOPINAVIR/RITONAVIR (LPV/R) AND ATAZANAVIR PLUS RITONAVIR (ATV VE HIV-I INFECTED PATIENTS BASED ON CASTLE 48-WEEK STUDY- APPLICATION TO GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72944-2&doi=10.1016/S1098-3015(10)72944-2
First page :
Section Title :
Open access? :
No
Section Order :
520